Dr. Trevor C. Morrison, M.D.
Radiology (Diagnostic Radiology Physician)
- Medicare participating
At a glance
- Medical school
- New York Medical College (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 1,336
Licensed in Illinois since 2021, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: New York Medical College
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Diagnostic Radiology Physician primary
IL license 036159065 (first issued 2021; active) · MA license 262871 · MI license 4301508455 · NY license 312047
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- North Shore University Hospital Manhasset, NY
- Conemaugh Memorial Medical Center Johnstown, PA
- Conemaugh Nason Medical Center Roaring Spring, PA
- Conemaugh Miners Medical Center Hastings, PA
- Conemaugh Meyersdale Medical Center Meyersdale, PA
Medical groups
- North Shore-Lij Medical PC (6,440 clinicians)
- Optum Medical Care PC (1,010 clinicians)
- Lenox Hill Radiology and Medical Imaging Associates PC (244 clinicians)
- Southside Faculty Medical Affiliates University Faculty Practice Corp (231 clinicians)
- Central Illinois Radiological Associates LTD (209 clinicians)
- Zwanger and Pesiri Radiology Group LLP (93 clinicians)
- Cira Michigan PC (91 clinicians)
- Maryland Imaging Network PC (81 clinicians)
- Cambria Somerset Radiology and Nuclear Medicine Group Inc (43 clinicians)
- Sierra Hematology and Oncology Medical Centers (16 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,336
- Services billed
- 14,424
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Ct scan of chest with contrast | 474 | 450 |
| Ct scan of abdomen and pelvis with contrast | 415 | 398 |
| Ct scan of chest without contrast | 231 | 227 |
| Ct scan of abdomen and pelvis without contrast | 94 | 94 |
| Mri scan of abdomen before and after contrast | 82 | 82 |
| Ct scan of blood vessels of chest with contrast | 66 | 66 |
| Ct scan of abdomen and pelvis before and after contrast | 46 | 46 |
| Limited ultrasound scan of abdomen | 32 | 32 |
| Low dose ct scan of chest for lung cancer screening | 26 | 26 |
| Complete ultrasound scan behind abdominal cavity | 21 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $84,158 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiat…
Amgen Inc. - A phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with …
AstraZeneca UK Limited - Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, …
Boehringer Ingelheim International GmbH - A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie Inc. · Recruiting · NCT04928846 - A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or…
Amgen Inc. - A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.